Research Correspondence
Dec 19
Victor J.M. Zeijen, Joost Daemen, et al.
Endovascular ultrasound renal denervation (uRDN) significantly reduced daytime ambulatory systolic blood pressure by 5.9 mmHg compared to sham at 2 months in patients with resistant hypertension, with the effect maintained after adjusting for changes in antihypertensive medications.
open access
Research Correspondence
Dec 18
Ghilas Rahoual, Michel Zeitouni, etc.
This study used a standardized approach combining hyperaemic absolute microvascular resistance and microvascular resistance reserve to differentiate four distinct phenotypes of coronary microvascular dysfunction.
Original Research
Dec 17
Roberto Galea, Lorenz Räber, et al.
This study compared the Watchman FLX and Watchman 2.5 left atrial appendage closure devices, finding significantly lower rates of device-related thrombus and peridevice leak with the Watchman FLX.
State-of-the-Art
Dec 16
Josep Rodés-Cabau, William T. Abraham, et al.
This content covers a range of cardiology interventions, including coronary, valvular, heart failure, peripheral, hypertension, and stroke treatments, as well as the use of advanced technologies like bioresorbable scaffolds and TAVI.
free
new issue
Dec 15
State-of-the-Art on TEER in MR; Watchman FLX vs 2.5; predictors of underexpansion with ACURATE neo; valve-in-root TAVI; CMD endotypes using invasive exercise testing; SORT OUT X: 5-year results; antihypertensive drugs in RADIANCE-HTN TRIO
Original Research
Dec 10
Antonio Landi, Marco Valgimigli, et al.
In high bleeding risk patients undergoing PCI, abbreviated antiplatelet therapy was associated with similar ischemic outcomes and reduced bleeding compared to standard therapy, regardless of chronic kidney disease status.
Editorial
Dec 12
Guillaume Marquis-Gravel, Renato D. Lopes
The content discusses the potential benefits of a shorter duration (1-3 months) of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI).
free
State-of-the-Art
Dec 8
Ziad A. Ali, Doosup Shin, et al.
Calcified nodules (CNs) pose challenges in percutaneous coronary intervention (PCI) due to their complex morphology and variable treatment responses. CNs are classified into eruptive and non-eruptive subtypes, with distinct features and prognostic implications.
free
Flashlight
Dec 1
Leonardo Portolan, Giovanni Luigi De Maria, et al.
This case report describes the successful implantation of a double coronary sinus Reducer device in a patient with refractory angina, complicated by proximal migration of the initial Reducer and subsequent coronary sinus thrombosis detected by cardiac CT.
Editorial
Dec 5
Johanne Silvain, Niki Procopi
A meta-analysis of 23,531 post-MI patients found that beta blocker use may only provide a modest morbidity reduction, and withdrawal may be safe for some, but continuation remains relevant for most post-MI patients.
free
Original Research
Dec 3
Xavier Rossello, Borja Ibanez, et al.
In patients with myocardial infarction and LVEF >40%, beta blocker withholding or withdrawal at discharge was not associated with increased short-term or recurrent ischaemic events.
open access
State-of-the-Art
Dec 2
Mila Kovacevic, Vijay Kunadian, et al.
This review provides a comprehensive overview of current evidence-based approaches to the management of non-ST-segment elevation acute coronary syndrome, focusing on diagnosis, risk stratification, and treatment strategies.
free
new issue
Dec 1
State-of-the-Art on the management of NSTE-ACS; State-of-the-Art on calcified nodules and PCI; beta blockers after MI; abbreviated antiplatelet therapy in HBR patients with CKD; thrombosis after Reducer migration
.jpg)
letter to the editor
Nov 27
Nikolaos Pyrpyris, Konstantinos Tsioufis, et al.
This letter discusses the need to evaluate the addition of novel pharmacotherapy to current regimens in order to improve outcomes related to leaflet thrombosis and cerebral injury after TAVI procedures.
free
letter to the editor
Nov 27
Victor Alfonso Jimenez Diaz, Paula Bellas Lamas, et al.
The reply adresses the need for further research on optimal post-TAVI regimens to balance ischaemic, embolic, bleeding, and cognitive risks, and the prevention of covert brain injury in the TAVI population.
free
